Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
Community Health Systems (CYH) Swings to Q3 Loss as Revenues Drop 10.7% and Guidance Is Cut

Community Health Systems (CYH) Swings to Q3 Loss as Revenues Drop 10.7% and Guidance Is Cut

Key Takeaways

  • Community Health Systems (CYH) posted a net loss attributable to stockholders of $86 million, or $0.63 per share, in the third quarter of 2026, compared with net income of $130 million, or $0.96 per share, a year earlier.
  • Adjusted EPS came in at a loss of $0.48, missing the consensus estimate of roughly a $0.29 loss.
  • Net operating revenues declined 10.7% year over year to $2.76 billion, below the approximately $2.80 billion analysts had projected.
  • Same-store revenues increased 3.8%, with same-store admissions up 2.2% and adjusted admissions up 3.6%, showing that core operations performed better than the reported headline figures.
  • Adjusted EBITDA fell 25.5% to $280 million, reflecting divestitures, an unfavorable payer mix, and higher medical specialist fees.
  • The company reduced its full-year 2026 outlook for revenue, adjusted EBITDA, and loss per share.
  • Additional detail is available on the company’s dedicated pages covering major news, price moves, price targets, and forecasts.

Earnings Context and Why It Matters

Community Health Systems (CYH) remains one of the largest hospital operators in the country and has been reshaping its portfolio through divestitures while navigating cost pressures. This quarter’s report is useful because it shows how the remaining same-store facilities are performing as divested hospitals drop out of the top line. The results also shed light on payer-mix trends, specialist fee inflation, and supplemental reimbursement costs. Following a narrower loss in the second quarter, these figures help clarify whether management’s expectations for a stronger second half are on track.

Reported Results

For the third quarter ended September 30, 2026, Community Health Systems (CYH) recorded a net loss attributable to stockholders of $86 million, or $0.63 per share, versus net income of $130 million, or $0.96 per share, in the same period last year. On an adjusted basis, the company posted a loss of $0.48 per share compared with earnings of $1.27 per share a year earlier, falling short of the consensus estimate of roughly a $0.29 loss.

Net operating revenues declined 10.7% to $2.76 billion from $3.09 billion, missing the roughly $2.80 billion consensus forecast. The drop was driven mainly by divestitures, although same-store revenue rose 3.8% on the back of 2.2% growth in same-store admissions and 3.6% growth in adjusted admissions. Adjusted EBITDA decreased 25.5% to $280 million from $376 million, pressured by an unfavorable payer mix, lower non-patient revenue, and higher medical specialist fees along with supplemental reimbursement program expenses. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Market Reaction and Investor Sentiment

Shares fell roughly 12% in after-hours trading after the release. The revenue and adjusted EPS misses, together with the downward revision to full-year guidance, appeared to outweigh the positive same-store trends. Investor sentiment had already been cautious ahead of the report, reflecting concerns about divestiture-related revenue declines, ongoing payer-mix challenges, and the durability of cost-control measures. The guidance cut reinforced those concerns by indicating that management anticipates weaker profitability for the rest of the year.

Forward Outlook and Key Factors to Monitor

Community Health Systems (CYH) lowered its 2026 guidance, now expecting net operating revenues of $11.3 billion to $11.5 billion, adjusted EBITDA of $1.225 billion to $1.275 billion, and a net loss per share of $1.60 to $1.70. The previous outlook had called for revenue of $11.40 billion to $11.60 billion, adjusted EBITDA of $1.300 billion to $1.375 billion, and a loss per share of $1.10 to $1.25.

Several factors deserve attention in coming quarters. Same-store volume trends remain important, as underlying admissions and adjusted admissions continued to grow despite the revenue impact from divestitures. Payer mix is another key variable, given the margin pressure from shifts toward lower-reimbursement coverage. Specialist fee inflation and supplemental reimbursement program costs also warrant monitoring because of their direct effect on adjusted EBITDA. Finally, any further portfolio changes or debt-reduction steps could influence both the top line and balance-sheet strength. Management’s commentary on the upcoming conference call should provide more color on whether the same-store recovery can offset these headwinds. From what I see, the same-store momentum is worth watching closely.

Using AI Tools in My Research Process

I regularly use Tickeron’s AI Screener when reviewing earnings reports like this one. The tool lets me quickly filter healthcare stocks by technical patterns, fundamentals, and performance metrics, helping surface comparable names and signals that might otherwise take hours to identify manually. It has become a practical part of my workflow for putting individual company results into broader context.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CYH

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


CYH's Indicator enters downward trend

The Aroon Indicator for CYH entered a downward trend on November 20, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 230 similar instances where the Aroon Indicator formed such a pattern. In 202 of the 230 cases the stock moved lower. This puts the odds of a downward move at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CYH as a result. In 68 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

The Moving Average Convergence Divergence Histogram (MACD) for CYH turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 42 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.

CYH moved below its 50-day moving average on October 27, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CYH crossed bearishly below the 50-day moving average on October 27, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYH advanced for three days, in 221 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

CYH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.224) is normal, around the industry mean (204.532). P/E Ratio (1.176) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.498). Dividend Yield (0.452) settles around the average of (0.153) among similar stocks. P/S Ratio (0.034) is also within normal values, averaging (2.688).

The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. CYH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 5.37B. The market cap for tickers in the group ranges from 20.9K to 107.17B. HCA holds the highest valuation in this group at 107.17B. The lowest valued company is NMMCF at 20.9K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was -12%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was 0%. CHE experienced the highest price growth at 0%, while NIVF experienced the biggest fall at -88%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was 13%. For the same stocks of the Industry, the average monthly volume growth was 102% and the average quarterly volume growth was 58%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 49
Price Growth Rating: 59
SMR Rating: 66
Profit Risk Rating: 83
Seasonality Score: -4 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an operator of general acute care hospitals

Industry HospitalNursingManagement

Industry
Hospital Or Nursing Management
Address
4000 Meridian Boulevard
Phone
+1 615 465-7000
Employees
57000
Web
https://www.chs.net
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.